去势抵抗性前列腺癌新型内分泌药物治疗次序的研究进展
发布时间：2018-12-27 08:15
【摘要】：近年来,中国的前列腺癌发病率逐年上升。大多数前列腺癌患者在初诊时已处于中晚期,虽然内分泌治疗在一定时期内可以使病情得到控制与改善,但经过18~24个月的中位缓解期后,绝大多数患者均进展为预后极差的转移性去势抵抗性前列腺癌(metastatic castration-resistant prostate cancer,m CRPC)。mCRPC的治疗颇为棘手,迫切需要优化其治疗策略来提高疗效。目前已有研究表明,新型内分泌药物如醋酸阿比特龙、恩杂鲁胺与多西紫杉醇化疗可以使mCRPC患者生存获益,但有关治疗次序的选择仍存在一定争议。本文对mCRPC患者在化疗前后接受不同次序的新型内分泌药物治疗相关的临床研究进展进行综述,以期为正确选择mCRPC治疗策略提供依据,进而延长患者的总生存期并提高生活质量。
[Abstract]:In recent years, the incidence of prostate cancer in China has increased year by year. The majority of prostate cancer patients are in the middle and late stage at the first visit. Although endocrine therapy can control and improve the disease in a certain period of time, but after 18 ~ 24 months of median remission period, Most of the patients developed into metastatic castrated resistant prostate cancer (metastatic castration-resistant prostate cancer,m CRPC). MCRPC) with poor prognosis. It is urgent to optimize the treatment strategy to improve the curative effect. Studies have shown that new endocrine drugs such as Abigitron Acetate, Enzaluramide and docetaxel chemotherapy can benefit the survival of patients with mCRPC, but the choice of treatment order is still controversial. This article reviews the clinical research progress of patients with mCRPC receiving new endocrine drugs in different order before and after chemotherapy, in order to provide the basis for the correct choice of mCRPC treatment strategy, and then prolong the total life span and improve the quality of life of patients.
【作者单位】： 天津医科大学肿瘤医院国家肿瘤临床医学研究中心天津市"肿瘤防治"重点实验室天津市恶性肿瘤临床医学研究中心;天津医科大学第二医院肿瘤科天津市泌尿外科研究所;
【基金】：国家自然科学基金资助项目(编号:81572543) 天津市卫生行业重点攻关项目(编号:14KG141)~~
【分类号】：R737.25
本文编号：2392764
[Abstract]:In recent years, the incidence of prostate cancer in China has increased year by year. The majority of prostate cancer patients are in the middle and late stage at the first visit. Although endocrine therapy can control and improve the disease in a certain period of time, but after 18 ~ 24 months of median remission period, Most of the patients developed into metastatic castrated resistant prostate cancer (metastatic castration-resistant prostate cancer,m CRPC). MCRPC) with poor prognosis. It is urgent to optimize the treatment strategy to improve the curative effect. Studies have shown that new endocrine drugs such as Abigitron Acetate, Enzaluramide and docetaxel chemotherapy can benefit the survival of patients with mCRPC, but the choice of treatment order is still controversial. This article reviews the clinical research progress of patients with mCRPC receiving new endocrine drugs in different order before and after chemotherapy, in order to provide the basis for the correct choice of mCRPC treatment strategy, and then prolong the total life span and improve the quality of life of patients.
【作者单位】： 天津医科大学肿瘤医院国家肿瘤临床医学研究中心天津市"肿瘤防治"重点实验室天津市恶性肿瘤临床医学研究中心;天津医科大学第二医院肿瘤科天津市泌尿外科研究所;
【基金】：国家自然科学基金资助项目(编号:81572543) 天津市卫生行业重点攻关项目(编号:14KG141)~~
【分类号】：R737.25
【相似文献】
相关期刊论文 前3条
1 尹绢;寇光;邱元芝;彭乐;陈发秀;;参芪扶正注射液联合内分泌药物治疗老年前列腺癌的疗效观察[J];实用癌症杂志;2014年01期
2 陆胜康;前列腺癌12例临床分析[J];中国肿瘤临床;1994年07期
3 张立;翁绳美;;前列腺癌内分泌药物治疗的现状与展望[J];海峡药学;2008年06期
，本文编号：2392764
本文链接：https://www.wllwen.com/yixuelunwen/zlx/2392764.html
